Inflammatory bowel disease (IBD) is a chronic gastrointestinal condition characterized by
severe gut inflammation, commonly presenting as Crohn's disease, ulcerative colitis or …

Neutralizing tumour necrosis factor (TNF) antibodies have been widely used to treat
inflammatory bowel disease (IBD) in the clinical practice. In this review, the principal …

The advent of anti-TNF agents as the first approved targeted therapy in the treatment of
inflammatory bowel disease (IBD) patients has made a major impact on our existing …

The use of biologic agents, particularly anti-tumor necrosis factor (TNF)-α, has revolutionized
the treatment of inflammatory bowel diseases (IBD), modifying their natural history. Several …

Crohn's disease and ulcerative colitis are chronic inflammatory gastrointestinal disorders
which often result in significant morbidity or surgery. Current treatment options are not …

Opinion statement Tumor necrosis factor-α (TNF-α) is an inflammatory cytokine that plays a
major role during the initiation and perpetuation of inflammatory bowel disease (IBD). Anti …

Introduction: Anti-tumor necrosis factor (TNF) agents have changed the therapeutic
approach to inflammatory bowel disease (IBD). However, a considerable proportion of …

Introduction: Crohn's disease (CD) and ulcerative colitis (UC) are chronic disabling
conditions. Monoclonal antibody therapy directed against tumor necrosis factor-alpha (anti …

Background Anti-TNFα represent one of the main treatment approaches for the management
of inflammatory bowel diseases (IBD). Therefore, the evaluation of their treatment patterns …

Monitoring anti-TNF agents in inflammatory bowel disease (IBD) patients may be helpful in
optimizing outcomes. We aimed to evaluate potential correlations among demographic …